Purpose. To assess whether there is a difference in associated drug costs for the management of chemo therapy-related side effects for patients with advanced colorectal cancer treated with raltitrexed (Tomudex, Zeneca Limited) or 5-FU plus folinic acid (Mayo regimen).
Data Sources. The drugs used for the manage ment of side effects were determined using a UK cohort (n = 62) taken from a large phase III ralti trexed clinical study. This study compared the toler ability and efficacy of raltitrexed vs 5-FU plus low- dose folinic acid and reported a significantly lower incidence of WHO grade 3/4 mucositis and leucope nia with raltitrexed. Drug costs were sourced using the British National Formulary, the Monthly Index of Medical Specialities and the Chemist and Druggist. Drug costs for the management of individual chemo therapy-related side-effects were calculated for both treatment groups and the total mean cost was com pared using the Student t test. Costs associated with the use of drugs for the management of clinically similar side effects, for example, nausea and vomiting were also investigated.
Results. There was a significant reduction in the mean total drug cost per patient for the management of chemotherapy-related side effects in the raltitrexed group compared to the 5-FU/folinic acid treatment group (£,64.27 vs £139.14; P = .0016). Infection was the most costly individual side effect for both treat ment groups but was lower in the raltitrexed cohort (£25.46 vs £59.93). Drug costs for the management of nausea and vomiting, pain and abdominal pain, and mucositis side effects were also considerably lower in the raltitrexed cohort.
Conclusion. The significantly lower drug cost for the management of chemotherapy-related side effects for the raltitrexed patients in the UK cohort suggests that the lower WHO grade 3/4 toxicity observed with raltitrexed in the phase III study would also be associated with a reduction in drug costs for the management of chemotherapy-related side ef fects.
Estève J, Kricker A, Ferlay J, et al, eds. Facts and figures of cancer in the European Community. Lyon, France: International Agency for Research on Cancer; 1993.
2.
Ross PJ, Cunningham D. Oncology: Chemotherapy of metastatic bowel cancer. Br J Hosp Med.1996; 55:263-266.
3.
Cunningham D. , Findlay M.The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer.1993;29A:2077-2079.
4.
Nordic Gastrointestinal Tumor Adjuvant Therapy Group.Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol.1992;10: 904-911.
5.
Scheithauer W., Rosen H., Komek G-V., et al. Randomised comparison of combination chemotherapy plus supportive care alone in patients with metastatic colorectal cancer. Br Med J.1993;306:752-755.
6.
Cunningham D. , Zalcberg JR, Rath U., et al. "Tomudex" (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer.1995;31A:1945-1954.
7.
Seitz JF, Cunningham D., Rath U., et al. Final results and survival data of a large randomised trial of "Tomudex" in advanced colorectal cancer (ACC) confirm comparable efficacy to 5-fluorouracil plus leucovorin (5-FU + LV) [Abstract]. Proc Am Soc Clin Oncol.1996;15:201.
8.
Kerr D. "Tomudex" (ZD1694), a new direct and specific thymidylate synthase inhibitor, has resource saving implications in the management of colorectal cancer. Qual Life Res. 1995;4:576.
9.
Leese B.The costs of treating febrile neutropenia in six U.K. hospitals. Eur J Cancer.1993;29A(suppl 7): S15-18.
10.
Leese B., Collin R., Clark DJThe costs of treating febrile neutropenia in patients with malignant blood disorders. Pharmacoeconomics.1994;6:233-239.
11.
Montero MC, Valdivia ML, Carvajal E., et al. Economic study of neutropenia induced by myelotoxic chemotherapy . Pharm World Sci.1994;16:187-191.
12.
Dranitsaris G., Tran TMEconomic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapy. Eur J Cancer.1995;31A:2174 -2180.
13.
Cunningham D., Gore M., Davidson N., et al. The real cost of emesis—an economic analysis of ondansetron vs metoclopramide in controlling emesis in patients receiving chemotherapy for cancer. Eur J Cancer.1993;29A:303-306.
14.
O'Brien BJ, Rusthoven J., Rocchi A., et al. Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. Can Med Assoc J.1993;149: 296-301.
15.
Johnson NE, Shoheiber O., Nash DBThe costs of treating toxicities in cancer chemotherapy patients [Abstract] . Proc Am Soc Clin Oncol.1995;14:524.
16.
Summerhayes M.Cost and pharmacy workload implications of "Tomudex" treatment. Inpharma. 1996;Suppl 2:10-11.
17.
Poon MA, O'Connell MJ, Wieand HS, et al. Biochemical modulation of fluorouracil with folinic acid: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol.1991;9:1967-1972.
18.
Buroker TR, O'Connell MJ, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and folinic acid in the treatment of advanced colorectal cancer. J Clin Oncol.1994;12:14-20.
19.
Lokich JJ, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus administration schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study. J Clin Oncol.1989;7:425- 432.
